Skip to main content
. 2022 Jun 22;12:904614. doi: 10.3389/fonc.2022.904614

Figure 8.

Figure 8

The drug sensitivity of (A) NVP.BEZ235, (B) BX795, (C) Tipifarnib, (D) Sorafenib, (E) MS.275, (F) Methotrexate between the low- and high-risk groups (p<0.01).